These results were consistent with others from similar clinical studies where PTX-3 expression was increased in patients diagnosed with prostatic cancer in comparison with those diagnosed with prostatic benign hyperplasia [32,37]. Here, PTX3 is linked to benign prostatic hyperplasia.